A clinical benefit full of life

POLIVY-R-CHP: the first clinically meaningful improvement over a standard of care that held for 20 years1-13

Watch experts perspectives

Specialist views covering a range of POLARIX trial topics

Dr Hervé Tilly

University of Rouen, France

Prof. Christopher Flowers

MD, Anderson Cancer Center, University of Texas

Dr Franck Morschhauser

MD, PhD Professor of Hematology,
University of Lille

Dr Laurie H. Sehn

MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia

reduced risk of progression, relapse, or death with 

POLIVY-R-CHP vs R-CHOP.1,*

That means more hope for the future, and more freedom from the threat of disease.

POLARIX Trial

What is the POLARIX trial?

A phase III trial to compare the efficacy and safety of polatuzumab vedotin in combination with R-CHP vs R-CHOP in 1L DLBCL1

Efficacy

Was a meaningful benefit seen for 1L DLBCL patients?

The POLIVY-R-CHP regimen demonstrated a clinically meaningful progression-free survival benefit over R-CHOP1

Safety

Were there any safety concerns?

The overall safety profile of POLIVY-R-CHP is similar to that of R-CHOP and consistent with the known risk of the individual study drugs1

“The new regimen should reduce the risk of relapse and help patients avoid intensive treatments such as stem cell transplantation and chimeric antigen receptor T-cell therapy.”14

– Dr Gilles Salles, MD, PhD

Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center

About POLIVY

Considering using
POLIVY-R-CHP for your patients?

Learn more about dosage, administration, and mechanism of action

*Stratified hazard ratio 0.73; 95% CI, 0.57–0.95; P=0.021
1L=first line; DLBCL=diffuse large B-cell lymphoma; POLIVY-R-CHP=polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, prednisone; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone.

 

References:

  1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
  2. Aurer I, et al. Eur J Haematol. 2011;86:111-6..
  3. Bartlett NL, et al. J Clin Oncol. 2019;37:1790-9.
  4. Coiffier B, et al. N Engl J Med. 2002;346:235-42.
  5. Cunningham D, et al. Lancet. 2013;381:1817-26.
  6. Davies A, et al. Lancet Oncol. 2019;20:649-62.
  7. Iacoboni G, et al. Ann Oncol. 2018;29:1120-9.
  8. Jaeger U, et al. Haematologica. 2015;100:955-63.
  9. Seymour JF, et al. Haematologica. 2014;99:1343-9.
  10. Vitolo U, et al. J Clin Oncol. 2017;35:3529-37.
  11. Vitolo U, et al. Hematol Oncol. 2019;37:36-7.
  12. Witzig TE, et al. Ann Oncol. 2018;29:707-14.
  13. Younes A, et al. J Clin Oncol. 2019;37:1285-95.
  14. ASCO Post. 2021 [cited 2022 15 July]. Available from: https://ascopost.com/news/december-2021/polarix-pola-r-chp-vs-r-chop-for-previously-untreated-patients-with-dlbcl/.